Samsung bioepis has invested $1 billion to enter the U.S. generic drug market

Source: Biovalley, August 24, 2015, with the advent of the patent cliff, many biomedical companies lost patent protection for their best-selling drugs The biosimilars market has also become a new field that can not be ignored by everyone This field has not only attracted the attention of traditional biomedical giants such as Novartis, but also the electronic giants such as Samsung Recently, Samsung bioepis, a joint venture of South Korea's Samsung and Baijian, announced that it would invest US $1 billion to enter the bio generic pharmaceutical market At present, the company has hired a group of experienced executives to operate The company hopes to take advantage of the patent cliff to enter the bio generic market It is predicted that in the next five years, the annual sales volume of European and American bio generic pharmaceutical market will reach an amazing 35 billion US dollars Ten of the best-selling drugs will be strongly impacted by generic drugs Humira, rituxan, Herceptin, Avastin, neupogen, neulasta and Epogen are all the best-selling drugs sweeping the market (related reading: in 2020, bio generic drugs will take half of the original research drug market.) this time, Samsung bio Epis company focused on the drugs such as embrel, REMICADE of Johnson & Johnson, Herceptin of Roche and Humira of Aberdeen In addition, the company also has an Avastin generic drug in the clinical phase I research stage At present, the company is the farthest away from the generic research project of Lantus, the Sanofi best-selling drug, which is currently in the phase III clinical research The company hopes to submit it to the U.S FDA for approval in the second half of this year and land in the European market early next year In addition, Samsung bioepis also mentioned plans to raise funds by listing on NASDAQ However, as Korean companies are often controlled by families, investors often have doubts about their transparency, so it is not known whether Samsung bioepis will buy In general, Samsung bioepis's vision of playing a leading role in the generic market is good, but it is still a long way to go.